The Food and Drug Administration (FDA) today issued a public health advisory to inform patients and health care // providers about the suspended marketing of Tysabri (nataluzimab) while the agency and the manufacturer evaluate two serious adverse events reported with its use.
Tysabri, which received accelerated approval from FDA in November 2004, is an innovative treatment that represents a new approach to treating patients with relapsing forms of multiple sclerosis (MS).
"FDA worked with the company to make sure this information, even though preliminary, was given to physicians and patients as soon as possible and supports their decision to voluntarily suspend marketing as well as the use of the product in clinical trials. At the same time, FDA continues to believe Tysabri offers great hope to MS patients," said Dr. Steven Galson, Acting Director, FDA's Center for Drug Evaluation and Research (CDER). "Patients being treated with Tysabri should contact their physician to discuss appropriate alternative treatments while these reports are being evaluated," added Dr. Galson.
FDA received a report from Biogen Idec, the manufacturer of Tysabri, of one confirmed fatal case and one possible case of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri for MS. FDA was given preliminary information about these cases by Biogen, Idec on February 18, 2005. Details became available to FDA the next week.
PML is a rare, serious progressive neurologic disease usually occurring in immunosuppressed patients. There is no known effective treatment for PML. Although the relationship between Tysabri and PML is not known at this time, because of the serious and often fatal nature of PML, FDA concurred with the company that the drug be voluntarily withdrawn from marketing and that the use of Tysabri in clinical trials be suspended until more is known.
During the review of Tysabri for marketing app
'"/>Page: 1 2 Related medicine news :1.
Unsatisfactory Grade On Womens Health Issues 2.
Who Board To Discuss Asian Tsunami Related Health Issues3.
WHO Issues Caution Against Bird Flu Epidemic4.
Sepsis Death Reported With Mifepristone – FDA Issues Warnin5.
High Court Issues Notice To Centre On Smoking Ban In Films6.
JRRD Focuses On Issues Such As Spinal Cord Injury and Prosthetics7.
China Issues New Legislation To Ban Human Organ Trade8.
Court Issues Order NACO On Gay Issue9.
NGOs and Various Groups Come Together To Address the Issues on AIDS10.
Budhias Medical Report Fails to Address Long Term Health Issues11.
HFEA Issues Warning On Risks Of Multiple Births With IVF